Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, EXC and QD

EXC, QD

NEW YORK, NY / ACCESSWIRE / January 30, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Adamas Pharmaceuticals, Inc. (NASDAQGM:ADMS)
Class Period: August 8, 2017 to September 30, 2019
Lead Plaintiff Deadline: February 10, 2020

Throughout the class period, Adamas Pharmaceuticals, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) health insurers were excluding Adamas's primary product, GOCOVRI, from their prescription formularies or requiring patients to use "step therapy" - i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) as a result of the foregoing, the Company's financial statements about Adamas's business, operations, and prospects were materially false and misleading at all relevant times.

Learn about your recoverable losses in ADMS: http://www.kleinstocklaw.com/pslra-1/adamas-pharmaceuticals-inc-loss-submission-form?id=5384&from=1

Exelon Corporation (NYSE:EXC)
Class Period: February 9, 2019 to November 1, 2019
Lead Plaintiff Deadline: February 14, 2020

The EXC lawsuit alleges that Exelon Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) Exelon and/or its employees were engaged in unlawful lobbying activities; (ii) the foregoing increased the risk of a criminal investigation into Exelon; (iii) Exelon subsidiary Commonwealth Edison's revenues were in part the product of unlawful conduct and thus unsustainable; and (iv) that, as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in EXC: http://www.kleinstocklaw.com/pslra-1/exelon-corporation-loss-submission-form?id=5384&from=1

Qudian Inc. (NYSE:QD)
Class Period: December 13, 2018 to January 15, 2020
Lead Plaintiff Deadline: March 23, 2020

The QD lawsuit alleges that throughout the class period, Qudian Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) regulatory developments in China threatened to negatively impact Qudian's fiscal full year 2019 ("FY19") financial results; (ii) Qudian's business was unprepared to mitigate the risks associated with these regulatory changes; (iii) as a result, Qudian's loan portfolio was plagued by growing delinquency rates; (iv) all of the foregoing made Qudian's repeated assertions concerning its FY19 financial guidance unrealistic; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in QD: http://www.kleinstocklaw.com/pslra-1/qudian-inc-loss-submission-form?id=5384&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/574687/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-ADMS-EXC-and-QD



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today